Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults
Author Information
Author(s): Thera Mahamadou A., Doumbo Ogobara K., Coulibaly Drissa, Diallo Dapa A., Kone Abdoulaye K., Guindo Ando B., Traore Karim, Dicko Alassane, Sagara Issaka, Sissoko Mahamadou S., Baby Mounirou, Sissoko Mady, Diarra Issa, Niangaly Amadou, Dolo Amagana, Daou Modibo, Diawara Sory I., Heppner D. Gray, Stewart V. Ann, Angov Evelina, Bergmann-Leitner Elke S., Lanar David E., Dutta Sheetij, Soisson Lorraine, Diggs Carter L., Leach Amanda, Owusu Alex, Dubois Marie-Claude, Cohen Joe, Nixon Jason N., Gregson Aric, Takala Shannon L., Lyke Kirsten E., Plowe Christopher V.
Primary Institution: Malaria Research and Training Center, University of Bamako, Bamako, Mali
Hypothesis
The study aimed to evaluate the safety, reactogenicity, and immunogenicity of the AMA-1-based malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria.
Conclusion
The FMP2.1/AS02A vaccine had a good safety profile, was well-tolerated, and was highly immunogenic in malaria-exposed adults.
Supporting Evidence
- The vaccine induced significant increases in anti-AMA-1 antibodies, peaking at nearly 5-fold and more than 6-fold higher than baseline in the half-dose and full-dose groups, respectively.
- Transient local pain and swelling were common and more frequent in both malaria vaccine dosage groups than in the comparator group.
- No serious adverse events occurred during the study.
- Participants receiving the full dose of the malaria vaccine had significantly greater mean antibody responses compared to those receiving the comparator vaccine.
- Immunization with both doses of the malaria vaccine was followed by significant elevations in anti-AMA-1 antibodies.
- Local reactions were more frequent in both malaria vaccine groups than in the comparator group.
- All local solicited symptoms resolved without sequelae during the 8-day post-immunization periods.
- Longitudinal analyses suggested a dose-related antibody response with higher responses in the full-dose group.
Takeaway
Researchers tested a malaria vaccine on adults in Mali and found it was safe and helped their bodies make strong defenses against malaria.
Methodology
A phase 1 double blind randomized controlled dose escalation trial was conducted with 60 healthy, malaria-experienced adults who received either a malaria vaccine or a rabies vaccine.
Potential Biases
Potential bias due to the open-label nature of the trial and the small sample size.
Limitations
The study was not powered to detect differences between groups and had a small sample size.
Participant Demographics
Participants were healthy adults aged 18–55 years, with a mean age of 28 years, and included 11 females.
Statistical Information
P-Value
0.050
Confidence Interval
95% CI for geometric mean antibody titers
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website